Drug Profile
EF 40
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class Calcium regulators; Osteoporosis therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 04 Jul 2000 Discontinued-II for Postmenopausal osteoporosis in United Kingdom (PO)
- 09 Oct 1997 Phase-II clinical trials for Postmenopausal osteoporosis in United Kingdom (PO)
- 25 Sep 1996 New profile